vs
Side-by-side financial comparison of BCB BANCORP INC (BCBP) and TriSalus Life Sciences, Inc. (TLSI). Click either name above to swap in a different company.
BCB BANCORP INC is the larger business by last-quarter revenue ($26.2M vs $13.2M, roughly 2.0× TriSalus Life Sciences, Inc.). BCB BANCORP INC runs the higher net margin — -49.7% vs -73.9%, a 24.2% gap on every dollar of revenue. On growth, TriSalus Life Sciences, Inc. posted the faster year-over-year revenue change (59.8% vs 13.1%). BCB BANCORP INC produced more free cash flow last quarter ($34.9M vs $-2.5M). Over the past eight quarters, TriSalus Life Sciences, Inc.'s revenue compounded faster (43.0% CAGR vs 1.8%).
TriSalus Life Sciences, Inc. is a clinical-stage biotechnology company focused on advancing immuno-oncology and interventional oncology solutions. It develops proprietary targeted drug delivery technologies designed to improve treatment efficacy for patients with liver, pancreatic and other hard-to-treat solid tumors, primarily operating in North American markets via partnerships with clinical care and research institutions.
BCBP vs TLSI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $26.2M | $13.2M |
| Net Profit | $-12.0M | $-9.8M |
| Gross Margin | — | 86.7% |
| Operating Margin | -71.9% | -24.8% |
| Net Margin | -49.7% | -73.9% |
| Revenue YoY | 13.1% | 59.8% |
| Net Profit YoY | -467.6% | 3.5% |
| EPS (diluted) | $-0.73 | $-0.22 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $26.2M | $13.2M | ||
| Q3 25 | $26.5M | $11.6M | ||
| Q2 25 | $25.2M | $11.2M | ||
| Q1 25 | $23.8M | $9.2M | ||
| Q4 24 | $23.1M | $8.3M | ||
| Q3 24 | $26.2M | $7.3M | ||
| Q2 24 | $20.4M | $7.4M | ||
| Q1 24 | $25.3M | $6.5M |
| Q4 25 | $-12.0M | $-9.8M | ||
| Q3 25 | $4.3M | $-10.8M | ||
| Q2 25 | $3.6M | $-8.3M | ||
| Q1 25 | $-8.3M | $-10.4M | ||
| Q4 24 | $3.3M | $-10.1M | ||
| Q3 24 | $6.7M | $-2.4M | ||
| Q2 24 | $2.8M | $-4.3M | ||
| Q1 24 | $5.9M | $-13.2M |
| Q4 25 | — | 86.7% | ||
| Q3 25 | — | 83.5% | ||
| Q2 25 | — | 83.9% | ||
| Q1 25 | — | 83.7% | ||
| Q4 24 | — | 85.3% | ||
| Q3 24 | — | 86.3% | ||
| Q2 24 | — | 87.6% | ||
| Q1 24 | — | 85.0% |
| Q4 25 | -71.9% | -24.8% | ||
| Q3 25 | 21.9% | -77.9% | ||
| Q2 25 | 19.9% | -65.4% | ||
| Q1 25 | -49.2% | -79.9% | ||
| Q4 24 | 19.9% | -91.8% | ||
| Q3 24 | 35.7% | -118.9% | ||
| Q2 24 | 19.5% | -111.0% | ||
| Q1 24 | 33.0% | -180.8% |
| Q4 25 | -49.7% | -73.9% | ||
| Q3 25 | 16.1% | -93.5% | ||
| Q2 25 | 14.2% | -73.9% | ||
| Q1 25 | -35.0% | -113.2% | ||
| Q4 24 | 14.1% | -122.4% | ||
| Q3 24 | 25.5% | -32.6% | ||
| Q2 24 | 13.8% | -58.8% | ||
| Q1 24 | 23.2% | -204.5% |
| Q4 25 | $-0.73 | $-0.22 | ||
| Q3 25 | $0.22 | $-0.96 | ||
| Q2 25 | $0.18 | $-0.27 | ||
| Q1 25 | $-0.51 | $-0.39 | ||
| Q4 24 | $0.17 | $-0.38 | ||
| Q3 24 | $0.36 | $-0.12 | ||
| Q2 24 | $0.14 | $-0.21 | ||
| Q1 24 | $0.32 | $-0.60 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $20.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $304.3M | $-33.9M |
| Total Assets | $3.3B | $35.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $20.4M | ||
| Q3 25 | — | $22.7M | ||
| Q2 25 | — | $26.5M | ||
| Q1 25 | — | $13.0M | ||
| Q4 24 | — | $8.5M | ||
| Q3 24 | — | $11.3M | ||
| Q2 24 | — | $16.5M | ||
| Q1 24 | — | $4.0M |
| Q4 25 | $304.3M | $-33.9M | ||
| Q3 25 | $318.5M | $-26.7M | ||
| Q2 25 | $315.7M | $-19.4M | ||
| Q1 25 | $314.7M | $-34.4M | ||
| Q4 24 | $323.9M | $-25.9M | ||
| Q3 24 | $328.1M | $-20.4M | ||
| Q2 24 | $320.7M | $-25.3M | ||
| Q1 24 | $320.1M | $-36.0M |
| Q4 25 | $3.3B | $35.3M | ||
| Q3 25 | $3.4B | $36.5M | ||
| Q2 25 | $3.4B | $41.3M | ||
| Q1 25 | $3.5B | $28.6M | ||
| Q4 24 | $3.6B | $24.0M | ||
| Q3 24 | $3.6B | $27.5M | ||
| Q2 24 | $3.8B | $32.4M | ||
| Q1 24 | $3.8B | $17.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.9M | $-2.5M |
| Free Cash FlowOCF − Capex | $34.9M | $-2.5M |
| FCF MarginFCF / Revenue | 133.3% | -19.1% |
| Capex IntensityCapex / Revenue | 4.0% | 0.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $58.2M | $-19.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $35.9M | $-2.5M | ||
| Q3 25 | $8.7M | $-3.7M | ||
| Q2 25 | $10.3M | $-7.3M | ||
| Q1 25 | $5.0M | $-4.5M | ||
| Q4 24 | $67.7M | $-5.7M | ||
| Q3 24 | $43.5M | $-10.8M | ||
| Q2 24 | $8.1M | $-13.4M | ||
| Q1 24 | $8.3M | $-10.9M |
| Q4 25 | $34.9M | $-2.5M | ||
| Q3 25 | $8.5M | $-3.9M | ||
| Q2 25 | $10.2M | $-7.4M | ||
| Q1 25 | $4.7M | $-5.3M | ||
| Q4 24 | $66.5M | $-5.8M | ||
| Q3 24 | $43.4M | $-11.0M | ||
| Q2 24 | $8.1M | $-13.5M | ||
| Q1 24 | $8.1M | $-10.9M |
| Q4 25 | 133.3% | -19.1% | ||
| Q3 25 | 32.0% | -33.9% | ||
| Q2 25 | 40.4% | -66.1% | ||
| Q1 25 | 19.8% | -57.3% | ||
| Q4 24 | 287.5% | -69.7% | ||
| Q3 24 | 166.0% | -149.9% | ||
| Q2 24 | 39.6% | -183.1% | ||
| Q1 24 | 32.3% | -169.3% |
| Q4 25 | 4.0% | 0.3% | ||
| Q3 25 | 1.1% | 1.9% | ||
| Q2 25 | 0.6% | 0.8% | ||
| Q1 25 | 1.2% | 8.2% | ||
| Q4 24 | 5.3% | 0.6% | ||
| Q3 24 | 0.3% | 2.3% | ||
| Q2 24 | 0.2% | 0.8% | ||
| Q1 24 | 0.6% | 1.0% |
| Q4 25 | — | — | ||
| Q3 25 | 2.05× | — | ||
| Q2 25 | 2.90× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 20.70× | — | ||
| Q3 24 | 6.53× | — | ||
| Q2 24 | 2.88× | — | ||
| Q1 24 | 1.41× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
